Log In Sign up
The largest database of trusted experimental protocols

GNA13 is a laboratory reagent used for research purposes. It is a guanine nucleotide-binding protein subunit alpha 13 that plays a role in cellular signaling pathways. The core function of GNA13 is to facilitate the transduction of extracellular signals into intracellular responses.

Automatically generated - may contain errors

Lab products found in correlation

Secondary fluorescent antibodies, by Abcam (2 mentions) Rock inhibitor y2763, by Merck Group (2 mentions) Tead1, by Santa Cruz Biotechnology (2 mentions) Pcdna3, by Addgene (2 mentions) Shyap1 2, by Addgene (2 mentions) Rgs12 antibody ab1, by Merck Group (2 mentions) Pdz domain peptides of rgs12, by GenScript (2 mentions) Gpcr activator lpa, by Merck Group (2 mentions) Gpcr inhibitor ki6425, by Merck Group (2 mentions) Rho gtpases inhibitor c3, by Merck Group (2 mentions) Tead1 sirna and controls, by Santa Cruz Biotechnology (2 mentions) Pcdna3.1 gfp yap, by Addgene (2 mentions) Pet gst yap, by Addgene (2 mentions) Pcdna3.1 rhoa, by Addgene (2 mentions) Shrgs12 1, by Applied Biological Materials (2 mentions) Shrgs12 2, by Applied Biological Materials (2 mentions) Shrgs12 3, by Applied Biological Materials (2 mentions) Edta free cocktail inhibitor tablets, by Thermo Fisher Scientific (2 mentions) Fugene hd transfection reagent, by Promega (2 mentions)

Close spelling variants of this product

GNA13 (sc-410)

2 protocols using gna13

1

Dissecting YAP/TEAD Signaling Pathway

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies against p127YAP (D9W2I), YAP (D8H1X), MST1, pMST (E7UD1), LATS1 (C66B5), pLATS1, Lamin B1 (D9V6H) and GAPDH were from CST. Antibodies of Ezrin, GNA12, GNA13, RhoA, flag, TEAD1, GST and GFP were from Santa Cruz Biotechnology. RGS12 antibody (ab1) was from Sigma. The secondary fluorescent antibodies were from Abcam. PDZ domain peptides of RGS12 were purchased from GenScript. GPCR activator LPA, GPCR inhibitor Ki6425, Rho GTPases inhibitor C3 and Rock inhibitor ‎Y2763 were obtained from Sigma. Doxorubicin hydrochloride (DOX), methotrexate 4-Amino-10-methylfolic acid hydrate (MTX) and EDTA-free cocktail inhibitor tablets were all obtained from Fisher Scientific™. TEAD1 siRNA and controls were from Santa Cruz Biotechnology. FuGENE® HD Transfection Reagent was purchased from Promega Corporation. The primers used for the quantification are listed in Supplementary Table 1.
The following plasmids: pRL-TK was generously provided by Dr. Zhen Zhang (University of Pennsylvania, Philadelphia, PA, USA); pcDNA3.1, shYAP1/2, pcDNA3.1-GFP-YAP, PET-GST-YAP and pcDNA3.1-RhoA were obtained from Addgene. Three human shRGS12 lentivectors (shRGS12–1, shRGS12–2 and shRGS12–3; Catalog # i019000) were ordered from ABM. pcDNA3.1-flag-RGS12 (flag-RGS12) and the pcDNA3.1-flag-RGS12 mutant with the deletion of the PDZ domain vectors (flag-RGS12ΔPDZ) were constructed in our lab.
Li Y., Liu M., Yang S., Fuller A.M., Eisinger T.S, & Yang S. (2021). RGS12 is a novel tumor suppressor in osteosarcoma that inhibits YAP-TEAD1-Ezrin signaling. Oncogene, 40(14), 2553-2566.
+ Open protocol
+ Expand
2

Dissecting YAP/TEAD Signaling Pathway

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies against p127YAP (D9W2I), YAP (D8H1X), MST1, pMST (E7UD1), LATS1 (C66B5), pLATS1, Lamin B1 (D9V6H) and GAPDH were from CST. Antibodies of Ezrin, GNA12, GNA13, RhoA, flag, TEAD1, GST and GFP were from Santa Cruz Biotechnology. RGS12 antibody (ab1) was from Sigma. The secondary fluorescent antibodies were from Abcam. PDZ domain peptides of RGS12 were purchased from GenScript. GPCR activator LPA, GPCR inhibitor Ki6425, Rho GTPases inhibitor C3 and Rock inhibitor ‎Y2763 were obtained from Sigma. Doxorubicin hydrochloride (DOX), methotrexate 4-Amino-10-methylfolic acid hydrate (MTX) and EDTA-free cocktail inhibitor tablets were all obtained from Fisher Scientific™. TEAD1 siRNA and controls were from Santa Cruz Biotechnology. FuGENE® HD Transfection Reagent was purchased from Promega Corporation. The primers used for the quantification are listed in Supplementary Table 1.
The following plasmids: pRL-TK was generously provided by Dr. Zhen Zhang (University of Pennsylvania, Philadelphia, PA, USA); pcDNA3.1, shYAP1/2, pcDNA3.1-GFP-YAP, PET-GST-YAP and pcDNA3.1-RhoA were obtained from Addgene. Three human shRGS12 lentivectors (shRGS12–1, shRGS12–2 and shRGS12–3; Catalog # i019000) were ordered from ABM. pcDNA3.1-flag-RGS12 (flag-RGS12) and the pcDNA3.1-flag-RGS12 mutant with the deletion of the PDZ domain vectors (flag-RGS12ΔPDZ) were constructed in our lab.
Li Y., Liu M., Yang S., Fuller A.M., Eisinger T.S, & Yang S. (2021). RGS12 is a novel tumor suppressor in osteosarcoma that inhibits YAP-TEAD1-Ezrin signaling. Oncogene, 40(14), 2553-2566.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!